Engineering HIV-specific immunity with chimeric antigen receptors

AIDS Patient Care and STDs

Volumn 30, Issue 12, 2016, Pages 556-561

  Kitchen, Scott G ^a   Zack, Jerome A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD8+ T cells; Chimeric antigen receptors; Engineered immunity; HIV immunity; Immunotherapy

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DNA MODIFICATION; FOLLOW UP; GENETIC MANIPULATION; HEMATOPOIETIC STEM CELL; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; STEM CELL GENE THERAPY; VIRAL GENE THERAPY; VIRUS IMMUNITY; VIRUS LOAD; VIRUS REPLICATION; CD4+ T LYMPHOCYTE; CYTOLOGY; DRUG EFFECTS; GENE THERAPY; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; PROCEDURES; VIROLOGY;

CD4-POSITIVE T-LYMPHOCYTES; GENETIC THERAPY; HIV; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; RECEPTORS, ANTIGEN; T-LYMPHOCYTES, CYTOTOXIC; VIRUS REPLICATION;

EID: 85002774820     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2016.0239     Document Type: Article

References (43)

1. Henrich TJ, Hanhauser E, Marty FM, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: Report of 2 cases. Ann Intern Med 2014;161:319-327.
2. Walker BD, Chakrabarti S, Moss B, et al. HIV-specific cytotoxic T-lymphocytes in seropositive individuals. Nature 1987;328:345-348.
3. Egelhofer M, Brandenburg G, Martinius H, et al. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol 2004;78:568-575.
4. Matano T, Shibata R, Siemon C, Connors M, Lane HC, Martin MA. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/ human immunodeficiency virus during primary infections of rhesus macaques. J Virol 1998;72:164-169.
5. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999;189:991-998.
6. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999;283:857-860.
7. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 1994;91:9770-9774.
8. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002;296: 1439-1443.
9. Allen TM, Altfeld M, Geer SC, et al. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 2005;79:13239-13249.
10. Allen TM, Yu XG, Kalife ET, et al. De novo generation of escape variant-specific CD8+ T-cell responses following cy-totoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol 2005;79:12952-12960.
11. Feeney ME, Tang Y, Pfafferott K, et al. HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol 2005;174:7524-7530.
12. Liu Y, McNevin J, Cao J, et al. Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol 2006;80:9519-9529.
13. Liu Y, McNevin J, Zhao H, et al. Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: Fitness-balanced escape. J Virol 2007;81:12179-12188.
14. International HIVCS, Pereyra F, Jia X, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010;330:1551-1557.
15. Yang OO, Kalams SA, Rosenzweig M, et al. Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T-lymphocytes. J Virol 1996;70:5799-5806.
16. Yang OO, Kalams SA, Trocha A, et al. Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: Evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 1997;71: 3120-3128.
17. Fesnak AD, June CH, Levine BL. Engineered T cells: The promise and challenges of cancer immunotherapy. Nat Rev Cancer 2016;16:566-581.
18. Holzinger A, Barden M, Abken H. The growing world of CAR T cell trials: A systematic review. Cancer Immunol Immunother 2016:1-18. doi: 10.1007/S00262-016-1895-5.
19. Joseph A, Zheng JH, Chen K, et al. Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. J Virol 2010;84:6645-6653.
20. Cooper LJ, Kalos M, Lewinsohn DA, Riddell SR, Green-berg PD. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol 2000;74: 8207-8212.
21. Varela-Rohena A, Carpenito C, Perez EE, et al. Genetic engineering of T cells for adoptive immunotherapy. Immunol Res 2008;42:166-181.
22. Varela-Rohena A, Molloy PE, Dunn SM, et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med 2008;14:1390-1395.
23. Deeks SG, Wagner B, Anton PA, et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 2002;5:788-797.
24. Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000;96:785-793.
25. Walker RE, Bechtel CM, Natarajan V, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000;96:467-474.
26. Vatakis DN, Arumugam B, Kim SG, Bristol G, Yang O, Zack JA. Introduction of exogenous T-cell receptors into human hematopoietic progenitors results in exclusion of endogenous T-cell receptor expression. Mol Ther 2013;21: 1055-1063.
27. Kitchen SG, Bennett M, Galic Z, et al. Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice. PLoS One 2009;4:e8208.
28. Kitchen SG, Levin BR, Bristol G, et al. In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLoS Pathog 2012; 8:e1002649.
29. Kitchen SG, Shimizu S, An DS. Stem cell-based anti-HIV gene therapy. Virology 2011;411:260-272.
30. Zhen A, Kamata M, Rezek V, et al. HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells. Mol Ther 2015;23:1358-1367.
31. Zhen A, Rezek V, Youn C, et al. Stem-cell based engineered immunity against HIV infection in the humanized mouse model. J Vis Exp 2016. doi: 10.3791/54048.
32. Ali A, Kitchen SG, Chen IS, Ng HL, Zack JA, Yang OO. HIV-1-Specific chimeric antigen receptors based on broadly neutralizing antibodies. J Virol 2016;90:6999-7006.
33. Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012;4:132ra153.
34. Roberts MR, Qin L, Zhang D, et al. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 1994;84: 2878-2889.
35. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 2014;20:119-122.
36. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188-195.
37. Yang OO, Tran AC, Kalams SA, Johnson RP, Roberts MR, Walker BD. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. Proc Natl Acad Sci U S A 1997;94:11478-11483.
38. Severino ME, Sarkis PT, Walker BD, Yang OO. Chimeric immune receptor T cells bypass class I requirements and recognize multiple cell types relevant in HIV-1 infection. Virology 2003;306:371-375.
39. Kamata M, Kim PY, Ng HL, et al. Ectopic expression of anti-HIV-1 shRNAs protects CD8(+) T cells modified with CD4zeta CAR from HIV-1 infection and alleviates impairment of cell proliferation. Biochem Biophys Res Commun 2015;463:216-221.
40. Kitchen SG, Jones NR, LaForge S, et al. CD4 on CD8+ T cells directly enhances effector function and is a target for HIV infection. Proc Natl Acad Sci U S A 2004;101:8727-8732.
41. Kitchen SG, Korin Y, Roth MD, Landay A, Zack JA. Costimulation of CD8+ lymphocytes induces CD4 expression and allows HIV-1 infection. J Virol 1998;72: 9054-9060.
42. Liu B, Zou F, Lu L, et al. CAR-T cells guided by the single-chain Fv of a broadly neutralizing antibody specifically and effectively eradicate the reactivated virus-latently-infected CD4+ T-lymphocytes isolated from HIV-1-infected individuals receiving suppressive cART. J Virol 2016;90:9712-9724.
43. Jamieson BD, Zack JA. In vivo pathogenesis of a human immunodeficiency virus type 1 reporter virus. J Virol 1998; 72:6520-6526.